SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.

SeaStar Medical Holding Corporation

SeaStar Medical is a medical device company developing novel cell-directed extracorporeal therapies to fight the life-threatening consequences of hyperinflammation.

SeaStar Medical

PRESS RELEASE: First Patient Enrolled in SeaStar Medical’s Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

Read the full release here: https://lnkd.in/ene8c5HJ

#pressrelease #medical #medicaldevices #clinicaltrials #medtech #ICU

SeaStar Medical is proud to announce our sponsorship of the inaugural season of the Critical Care Time (www.criticalcaretime.com) podcast by co-creators Nick Mark, MD (of ICU Onepager fame!) & Cyrus Askin, MD.

See the press release HERE: https://lnkd.in/enbP3puq

 #CritCareTime #ICU #OnePagerICU

At SeaStar Medical, we are fighting the effects of a dysregulated immune response. Here’s a closer look at how our novel Selective Cytopheretic Device (SCD) deactivates inflammatory neutrophils & monocytes to restore immune balance.

#MedDevice #ICU #immunesystem #medical

Learn how our Selective Cytopheretic Device (SCD) modulates immune effector cells responsible for a dysregulated immune response.

#MedTech #MedDevice #SCD #AKI #ICU

At SeaStar Medical, we are fighting the effects of a dysregulated immune response. Learn how this imbalance drives hyperinflammation and damage in acute kidney injury. More info at https://bit.ly/3PixGJE

#Hyperinflammation #AKI #ICU $ICU

SeaStar Medical to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21, 2023. Sign up now: https://lnkd.in/eTbbvsa3

Full Press Release: https://lnkd.in/eW5Da9e2
 
 #ICU #SeaStar #Hyperinflammation #CellDirectedTherapy #Kidney $ICU

SeaStar Medical is proud to support the ADQI Conference on Extracorporeal Therapies, June 9-12 in Vicenza, Italy

Learn more about ADQI's important initiatives at https://bit.ly/3Cpkrz6

#AKI #CriticalCare #ICU

Today our CMO, Dr. Kevin Chung, will be delivering "Novel Targets for Blood Purification - Pathogens, Endotoxins, Neutrophils, Oh My!" for the 7th Annual Southern California Kidney Symposium at 2PM PST - tune in to hear this exciting talk! https://lnkd.in/eRBGcSrK

#AKI #ICU $ICU

Hear from our very own Chief Medical Officer, Dr. Kevin Chung, on Novel Targets for Blood Purification this Friday June 9th at 2pm PST at the 7th Annual Southern California Kidney Symposium

Register now for this hybrid event: https://lnkd.in/eRBGcSrK

#AKI #ICU $ICU

	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue
gross profit
selling and marketing expenses
general and administrative expenses	2.43M -	1.68M 30.68%	6.60M 292.16%
selling general and administrative expenses	2.43M -	1.68M 30.68%	6.60M 292.16%	8.24M 24.80%
research and development expenses	4.03M -	2.77M 31.28%	2.82M 1.92%	5.97M 111.88%
other expenses	84K -	91K 8.33%
cost and expenses	6.45M -	4.45M 31.06%	11.61M 160.94%	14.21M 22.41%
operating expenses	6.45M -	4.45M 31.06%	11.61M 160.94%	14.21M 22.41%
interest expense	3.31M -	212K 93.59%	630K 197.17%	1.08M 71.59%
ebitda	-6.37M -	-4.36M 31.57%	-11.61M 166.38%	-14.21M 22.41%
operating income	-6.45M -	-4.45M 31.06%	-11.61M 160.94%	-14.21M 22.41%
depreciation and amortization	84K -	91K 8.33%
total other income expenses net	6.49M -	64K 99.01%	-10.77M 16,932.81%	-12.02M 11.59%
income before tax	-3.27M -	-4.60M 40.71%	-23.01M 400.59%	-26.23M 13.99%
income tax expense	9K -	-1K 111.11%	1K 200%
net income	-3.28M -	-4.60M 40.29%	-23.01M 400.72%	-26.23M 13.99%
weighted average shs out	7.24M -	7.24M 0%	8.21M 13.43%	21.67M 163.91%
weighted average shs out dil	7.24M -	7.24M 0%	8.21M 13.43%	21.67M 163.91%
eps	-0.45 -	-0.63 40%	-2.80 344.44%	-1.21 56.79%
epsdiluted	-0.45 -	-0.63 40%	-2.80 344.44%	-1.21 56.79%

COM:SEASTARMEDICAL

SeaStar Medical

Last Close

2.20

22/11 21:00

Market Cap

25.99M

Beta: -

Volume Today

141.03K

Avg: -

Preview